Compare CURV & ORMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CURV | ORMP |
|---|---|---|
| Founded | 2001 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.2M | 165.3M |
| IPO Year | 2021 | 2010 |
| Metric | CURV | ORMP |
|---|---|---|
| Price | $2.33 | $4.05 |
| Analyst Decision | Hold | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $1.59 | N/A |
| AVG Volume (30 Days) | 281.4K | ★ 516.0K |
| Earning Date | 06-04-2026 | 05-14-2026 |
| Dividend Yield | N/A | ★ 6.51% |
| EPS Growth | N/A | ★ 412.50 |
| EPS | N/A | ★ 0.91 |
| Revenue | ★ $1,000,092,000.00 | $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.15 | N/A |
| P/E Ratio | ★ N/A | $4.44 |
| Revenue Growth | N/A | ★ 49.25 |
| 52 Week Low | $0.94 | $1.98 |
| 52 Week High | $2.88 | $5.19 |
| Indicator | CURV | ORMP |
|---|---|---|
| Relative Strength Index (RSI) | 70.55 | 47.13 |
| Support Level | $1.03 | $3.83 |
| Resistance Level | N/A | $4.22 |
| Average True Range (ATR) | 0.17 | 0.25 |
| MACD | 0.03 | -0.06 |
| Stochastic Oscillator | 86.78 | 18.95 |
Torrid Holdings Inc is a direct-to-consumer brand in North America dedicated to offering a diverse assortment of stylish apparel, intimates, and accessories skillfully designed for curvy women. Its extensive collection features high-quality merchandise, including tops, bottoms, denim, dresses, intimates, activewear, footwear, and accessories. The company has one reportable segment, which includes the operation of its e-Commerce platform and stores.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.